NO924323L - Nye hybridtransformerende vekstfaktorer - Google Patents

Nye hybridtransformerende vekstfaktorer

Info

Publication number
NO924323L
NO924323L NO92924323A NO924323A NO924323L NO 924323 L NO924323 L NO 924323L NO 92924323 A NO92924323 A NO 92924323A NO 924323 A NO924323 A NO 924323A NO 924323 L NO924323 L NO 924323L
Authority
NO
Norway
Prior art keywords
growth factors
new hybrid
transforming growth
hybrid
tgf
Prior art date
Application number
NO92924323A
Other languages
English (en)
Other versions
NO924323D0 (no
Inventor
Gary Kent Mcmaster
David Cox
Nico Cerletti
Jochen Kuhla
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of NO924323D0 publication Critical patent/NO924323D0/no
Publication of NO924323L publication Critical patent/NO924323L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Nye hybrid TGF-e, en fremgangsmåte for fremstilling av biologisk aktive, dimere hybridprotelner og farma- søytiske sammensetningen som omfatter disse er beskrevet. Hybride TGF-e produsert ved denne fremgangs- måten kan bli anvendt l forskjellige terapeutiske metoder så som for å fremme og aksellerere leging av sår og ben og vevsreparering, behandling av cancer, som et benmargsbeskyttende middel, mediator for kardio- beskyttelse, antl-lnflammatorisk . eller immunsuppresivt middel eller som en vekstregulator i pattedyrcelle- kulturer.
NO92924323A 1991-11-11 1992-11-10 Nye hybridtransformerende vekstfaktorer NO924323L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP91810870 1991-11-11

Publications (2)

Publication Number Publication Date
NO924323D0 NO924323D0 (no) 1992-11-10
NO924323L true NO924323L (no) 1993-05-12

Family

ID=8208899

Family Applications (1)

Application Number Title Priority Date Filing Date
NO92924323A NO924323L (no) 1991-11-11 1992-11-10 Nye hybridtransformerende vekstfaktorer

Country Status (12)

Country Link
EP (1) EP0542679A1 (no)
JP (1) JPH05306297A (no)
KR (1) KR930010177A (no)
AU (1) AU2738392A (no)
CA (1) CA2082450A1 (no)
FI (1) FI925086A (no)
IL (1) IL103684A0 (no)
MX (1) MX9206456A (no)
NO (1) NO924323L (no)
NZ (1) NZ245047A (no)
TW (1) TW240231B (no)
ZA (1) ZA928647B (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8927546D0 (en) * 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
US5436228A (en) * 1990-12-12 1995-07-25 Postlethwaite; Arnold E. Chemotactic wound healing peptides
US5824647A (en) * 1990-12-12 1998-10-20 Postlethwaite; Arnold E. Chemotactic wound healing peptides
GB9106678D0 (en) * 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6395494B1 (en) 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6197789B1 (en) 1995-06-07 2001-03-06 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
JPH08510451A (ja) * 1993-05-13 1996-11-05 ネオルックス コーポレイション 異常増殖性平滑筋細胞に関連した病因の予防及び治療
TW440566B (en) * 1994-07-25 2001-06-16 Novartis Ag Novel process for the production of biologically active dimeric protein
TW517059B (en) 1994-07-25 2003-01-11 Ciba Geigy Ag New process for the production of biologically active protein
US6117911A (en) 1997-04-11 2000-09-12 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
EP1089764B1 (en) 1998-06-10 2004-09-01 Biognostik Gesellschaft für biomolekulare Diagnostik mbH Stimulating the immune system
AU2001238091A1 (en) * 2000-08-09 2002-02-18 Curis, Inc. Tgf-beta therapeutics, compositions and methods of use
JP2007531746A (ja) * 2004-04-02 2007-11-08 コーリー ファーマシューティカル グループ，インコーポレイテッド Ｉｌ−１０応答を誘導するための免疫活性化核酸
US9758786B2 (en) 2016-02-09 2017-09-12 Autotelic, Llc Compositions and methods for treating pancreatic cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ222168A (en) * 1986-10-20 1991-05-28 Oncogene Science Inc Tumour growth inhibiting protein related to tgf-#b#1 and tgf-#b#2, preparation by genetic engineering methods, antibodies and pharmaceutical compositions
US5221620A (en) * 1987-10-06 1993-06-22 Oncogen Cloning and expression of transforming growth factor β2
CA2005120A1 (en) * 1988-12-15 1990-06-15 Anthony F. Purchio Tgf-beta 1/beta 2: a novel chimeric transforming growth factor-beta
GB8927546D0 (en) * 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta

Also Published As

Publication number Publication date
ZA928647B (en) 1993-06-21
FI925086A0 (fi) 1992-11-09
CA2082450A1 (en) 1993-05-12
NZ245047A (en) 1995-04-27
IL103684A0 (en) 1993-04-04
NO924323D0 (no) 1992-11-10
JPH05306297A (ja) 1993-11-19
EP0542679A1 (en) 1993-05-19
AU2738392A (en) 1993-05-13
FI925086A (fi) 1993-05-12
TW240231B (no) 1995-02-11
KR930010177A (ko) 1993-06-22
MX9206456A (es) 1993-07-01

Similar Documents

Publication Publication Date Title
NO924323L (no) Nye hybridtransformerende vekstfaktorer
Wu et al. Wound care: the role of advanced wound-healing technologies
Viganò et al. Mesenchymal stem cells as therapeutic target of biophysical stimulation for the treatment of musculoskeletal disorders
Andreassi et al. A new model of epidermal culture for the surgical treatment of vitiligo
RU2010105646A (ru) Способ регенерации ткани
NO940597L (no) Isolering, vekst, differensiering og genslöyd på menneskers muskelceller
AU2293795A (en) Method of enhancing wound healing by stimulating fibroblast and keratinocyte growth (in vivo), utilizing amphipathic peptides
Cebrián et al. Comparative study of the use of electromagnetic fields in patients with pseudoarthrosis of tibia treated by intramedullary nailing
Tan et al. Low-intensity pulsed ultrasound (LIPUS) and pulsed electromagnetic field (PEMF) treatments affect degeneration of cultured articular cartilage explants
EP1405906A4 (en) SCHWANN CELLS FROM INTERSTITIAL MYELOID CELLS
US20030202965A1 (en) Methods and compositions for the preparation of cell transplants
WO2004011631A3 (en) Methods and compositions for treating tissue defects using pulsed electromagnetic field stimulus
Fimiani et al. Other uses of homologous skin grafts and skin bank bioproducts
Ghali et al. The direct effect of light therapy on endothelial cell proliferation in vitro
ATE513900T1 (de) Herstellung und verwendung von humanen cd124 und cd116 positiven tumorzelllinien zur herstellung von allogenen oder semi-allogenen immuntherapeutika
CN113713176B (zh) 一种水凝胶及其制备方法与应用
Kwon et al. Regeneration of Chronic Rotator Cuff Tear in a Rabbit Model: Synergetic Benefits of Human Umbilical Cord Blood‐Derived Mesenchymal Stem Cells, Polydeoxyribonucleotides, and Microcurrent Therapy
CA2332935A1 (en) A method for inducing production of growth factors
Fu Skin ulcers in lower extremities: the epidemiology and management in China
Liu et al. Laparoscopic harvest and free transplantation of great omentum flap for extensive tissue defects in complex wounds
Mester Biostimulative effect of laser beams
Lattes et al. Effect of Cartilage and Other Tissue Suspensions on Reparative Process of Cortisone-Treated Animals
RU2811662C1 (ru) Способ стимуляции заживления ожоговых травм в эксперименте
Рябошапко Mesenchymal stem cells: a promising means of activating reparative osteogenesis
TAKAHASHI et al. Effects of Atmospheric Low Temperature Pressure Plasma on Bone Fracture Mechanisms